Ovitrelle Solution for Injection contains 250 mcg of human chorionic gonadotropin (hCG), a glycoprotein hormone used primarily in assisted reproductive technology to induce final follicular maturation and ovulation. It mimics the natural luteinizing hormone (LH) surge, triggering ovulation in women undergoing controlled ovarian stimulation protocols as part of in vitro fertilization (IVF) or other fertility treatments. Ovitrelle is administered subcutaneously, typically once the ovarian follicles have reached an appropriate size, to promote the release of a mature oocyte. In addition to its use in female infertility treatments, hCG in Ovitrelle is also employed in males for the stimulation of testosterone production and spermatogenesis in cases of hypogonadotropic hypogonadism. The dosage and timing of administration should be carefully determined by a healthcare professional based on individual patient response and treatment protocol. Common side effects may include injection site reactions, headache, abdominal discomfort, and in rare cases, ovarian hyperstimulation syndrome (OHSS). Ovitrelle should be used under strict medical supervision, with monitoring of ovarian response to minimize risks. It is contraindicated in patients with hypersensitivity to hCG or any component of the formulation, and in cases of hormone-sensitive tumors.